Quarterly report pursuant to Section 13 or 15(d)

STOCK OPTIONS AND WARRANTS (Details Narrative)

STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock compensation expense	$ 11,688	$ 950,814	$ 1,642,241	$ 1,398,614
Stock compensation expense unamortized			$ 47,361
Weighted average remaining life			10 months 15 days
Option grants
Consultant [Member]
Option grants			53,280
Option grants value			$ 233,111
2018 Equity Incentive Plan [Member]
Stock option desscription			On May 15, 2018, the Board of Directors approved and adopted the BioCorRx Inc. 2018 Equity Incentive Plan (2018 Stock Option Plan) under which an aggregate of 450,000 shares may be issued. The plan shall terminate ten years after the plan’s adoption by the board of directors. The company has granted an aggregate of 368,280 stock options.
Option grantable			81,720
Option expired			1,500
2016 Equity Incentive Plan [Member]
Stock option desscription			On June 15, 2016, our board of Directors authorized and approved the adoption of the Equity Incentive Plan effective June 15, 2016 (2016 Equity Incentive Plan) under which an aggregate of 656,250 shares may be issued. The plan shall terminate ten years after the plan’s adoption by the board of directors. We granted an aggregate of 330,350 stock options.
Option grantable			325,900
Equity Incentive Plan 2014 [Member]
Stock option desscription			On November 13, 2014, our Board of Directors authorized and approved the adoption of the Plan effective November 13, 2014 (2014 Stock Option Plan) under which an aggregate of 20% (290,879 shares) of the issued and outstanding shares may be issued. The plan shall terminate ten years after the plan’s adoption by the board of directors. We granted an aggregate 146,500 stock options.
Option grantable			144,379
Stock Options [Member]
Intrinsic value of the vested stock options price	$ 3.15		$ 3.15